Drug firm Suven Life Sciences has been granted a patent from Europe and two product patents from Eurasia for a drug used in the treatment of neuro-degenerative diseases.
In a BSE filing today, Suven Life said it has been granted "one product patent from Europe and two product patents from Eurasia corresponding to New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases". The patents are valid through 2029, 2030 and 2031, respectively, the company added.
The market continued to hold its morning gains on the back of support from auto, pharma, IT and select banking & financial stocks.
The 30-share BSE Sensex rose 123.63 points to 26648.18 and the Nifty advanced 45.10 points to 8172.95.
The broader markets continued to outperform benchmarks as the BSE Midcap and Smallcap indices gained 0.9 percent and 1.1 percent, respectively.
The Cabinet in its today's meeting has cleared mineral exploration policy and recommendations related to 7th pay commission.
BUY NIFTY FUTURE ABOVE 8180 TG 8220, 8280 SL 8120,
In a BSE filing today, Suven Life said it has been granted "one product patent from Europe and two product patents from Eurasia corresponding to New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases". The patents are valid through 2029, 2030 and 2031, respectively, the company added.
The market continued to hold its morning gains on the back of support from auto, pharma, IT and select banking & financial stocks.
The 30-share BSE Sensex rose 123.63 points to 26648.18 and the Nifty advanced 45.10 points to 8172.95.
The broader markets continued to outperform benchmarks as the BSE Midcap and Smallcap indices gained 0.9 percent and 1.1 percent, respectively.
The Cabinet in its today's meeting has cleared mineral exploration policy and recommendations related to 7th pay commission.
BUY NIFTY FUTURE ABOVE 8180 TG 8220, 8280 SL 8120,







